Following is a cumulative list of Hoosier Cancer Research Network publications in pancreatic cancer.

Manuscripts and Journal Articles

• Cardenes HR, Moore AM, Johnson CS, Yu M, Helft P, Chiorean EG, Vinson J, Howard TJ, Stephens AW, Tai DF, Loehrer PJ Sr. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study GI00-11. Am J Clin Oncol. 2011 Oct;34(5):460-5.
• Cardenes HR, Moore AM, Johnson CS, Yu M, Helft P, Chiorean EG, Vinson J, Howard TJ, Stephens AW, Tai DF, Loehrer PJ Sr. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable pancreatic cancer: Hoosier Oncology Group GI00-11. Am J Clin Oncol. 2011 Oct:34(5):460-5. doi10.1097/ COC.0b013e3181e9c103. PMID: 20881474
• Schneider B, Ganjoo K, Seitz D, Picus J, Fata F, Stoner C, Calley, C, Loehrer P. Phase II study of gemcitabine and docetaxel in combination for advanced pancreatic cancer-a Hoosier Oncology Group study GI99-1. Oncology. 65(3):218-23, 2003
• Ganjoo Kristen N., Gordon Michael S., Sandler Alan B., Warner Ruth E., Fife Karen, Poirier Shelley, Seshadri Roopa, Loehrer Patrick J. A Phase I Study of Weekly Gemcitabine and Docetaxel in Patients with Advanced Cancer: A Hoosier Oncology Group Study GI98-1. Oncology 2002;62:299-304.
• Miller K, Loehrer PJ, Gonin R, Weber G, Ansari R, Pletcher W, McClean J, Spiridonidis CH, Mortimer J: Phase II Study of Weekly Oral Methotrexate and Zidovudine (AZT) in Advanced Adenocarcinoma of the Pancreas and Hepatocellular Carcinoma: Hoosier Oncology Group GI91-1. Invest New Drugs 14:207-212, 1996.

Abstracts, Posters, and Presentations

• Walid Labib Shaib, Manali Rupji, Tina Ashley Khair, Erwin L. Robin, Bassel F. El-Rayes, Timothy K. Huyck, Yuan Liu, Mohamad Bassam Sonbol, Tanios S. Bekaii-Saab. Phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). Presented as a Poster at the 2021 Gastrointestinal Cancers Symposium, January 15-17, 2021. J Clin Oncol 39, 2021 (suppl 3; abstr 413). See abstract.
• Walid Labib Shaib, Bert O’Neil, Bassel F. El-Rayes, Steven J. Cohen, Tina Ashley Khair, Erwin L. Robin, Timothy K. Huyck, Rebecca A. Redman, Ashwin Reddy Sama, Mohamad Kassar, Tanios S. Bekaii-Saab. Phase II randomized, double-blind, study of mfolfirinox plus ramucirumab versus mfolfirinox plus placebo in advanced pancreatic cancer patients HCRN GI14-198. Presented as a Trials in Progress Poster at the 2019 Gastrointestinal Cancers Symposium, January 18, 2019, San Francisco, CA. See abstract.
• A. M. Moore, H. Cardenes, C. S. Johnson, P. Helft, D. Seitz, A. Stephens, D. Fritz Tai, P. J. Loehrer. A Phase II Study of Gemcitabine in Combination with Radiation Therapy in Patients With Localized, Unresectable Pancreatic Cancer: Hoosier Oncology Group GI00-11. Accepted to the ASCO annual meeting June 5-8, 2004, New Orleans, LA.
• Bryan P Schneider, Kristen N Ganjoo, Lawrence H Einhorn, Joel Picus, Farid Fata, Patrick J Loehrer, Cindy Stoner. Phase II study of gemcitabine and docetaxel in combination for advanced pancreatic cancer: Hoosier Oncology Group GI98-1. Accepted as a poster presentation with discussion for ASCO annual meeting May 18-21, 2002, Orlando, FL.
• Mortimer J, Weber G, Fracasso P, Pletcher W, Ansari R. Phase I-II Study of Zidovudine (AZT) and Methotrexate (MTX) in Advanced Pancreatic Cancer and Hepatoma: A Hoosier Oncology Group and Walther Cancer Institute Trial GI91-1. Accepted to the ASCO Annual Meeting, May 14th – 17th, 1994, Dallas, Texas.
• Picus J, Dickerson G, Logie K, Ansari R, Markham R, Spiridonidis C. A Phase II Study of Unresectable Pancreatic Cancer Treated with 5-FU and Leucovorin with Radiation Therapy: A Hoosier Oncology Group and Walther Cancer Institute Trial GI89-2. Accepted to the ASCO Annual Meeting, May 14th – 17th, 1994, Dallas, Texas